Veminsyn

About Veminsyn

Veminsyn, also known as Weiming Shiguang, is a Chinese biotechnology firm founded in 2021 that specializes in the research, development, and production of bio-based active ingredients for the personal care and cosmetics industries. The company was established by a team of doctoral students from Peking and Tsinghua University: Yaran Zhao, Jiayue Chen, Yufan Li, and Xiaomei Lin. Their academic backgrounds in biology and biocatalysis from leading Chinese institutions form the scientific foundation of the company's operations.

The firm operates on a business-to-business model, supplying both raw materials and customized ingredient solutions to well-known beauty and personal care brands, including domestic Chinese companies like Zhuben, Helius, and Bloomage Biotech. Veminsyn's core strategy is to leverage synthetic biotechnology to create high-performance, sustainable alternatives to traditional cosmetic ingredients derived from animal, plant, or chemical synthesis. The company utilizes a multi-platform approach that integrates a large database of natural active molecules, AI-driven design, and high-throughput screening to discover and engineer novel bioactive compounds. A key technological advantage is their "molecular compression" technique, which reduces the size of molecules like collagen to enhance skin absorption without losing efficacy.

Veminsyn has secured significant financial backing, including a Series A round in October 2022 and a subsequent Series B round in May 2025, which raised nearly 100 million RMB (approximately $13.8M). This later funding round included a strategic investment from L'Oréal Group, through its BOLD venture capital arm and its China fund, as well as from the Nice Group, a major Chinese consumer goods company. This partnership with L'Oréal aims to co-develop unique bioactive ingredients and accelerate their path from design to large-scale production, signaling strong market confidence in Veminsyn's capabilities.